Medindia
Medindia LOGIN REGISTER
Advertisement

Global Cannabis Market Set to Grow as U.S and Canada Leads the Way

Tuesday, August 14, 2018 Drug News
Advertisement
FinancialBuzz.com News Commentary

NEW YORK, August 14, 2018 /PRNewswire/ --
Advertisement

According to data published by Forbes, citing Brightfield Group, the global cannabis market is projected to reach USD 31.4 Billion by 2021. By end of 2017, the global cannabis market value was estimated at USD 7.7 Billion, in which the U.S. held about 90% of total sales. By 2021, the U.S. is expected to account for only 57% of global cannabis sales. Meanwhile, the global market will continue to grow at a CAGR of 60%, as countries are in the process of easing regulations, opening the door for legal sales of cannabis products for both medical and recreational purposes. The Canadian market is expected to heavily contribute to the growing market, due to its recently passed bill to legalize recreational cannabis. Canada now joins Uruguay as the only countries to legalize cannabis on a federal level. Tidal Royalty Corp. (OTC: TDRYF), India Globalization Capital Inc. (NYSE: IGC), mCig Inc. (OTC: MCIG), Cannabics Pharmaceuticals Inc. (OTC: CNBX), Future Farm Technologies Inc. (OTC: FFRMF)
Advertisement

The legal cannabis market has become very competitive over the course of recent years. According to Brightfield Group's official blog post, "With cannabis dispensary and product data now going back over two years, our surveys of marijuana product availability in major US state markets reveal several clear indicators that the market is growing increasingly competitive and crowded… One example of this is exhibited by the increase in the variety of branded products available at US dispensaries. Two years ago, the average US dispensary carried 94 different types of branded marijuana products. One year ago, that number had grown to 118, and by January of this year, a typical dispensary carried over 150 different branded products."  

Tidal Royalty Corp. (OTC: TDRYF) is also listed on the Canadian Securities Exchange under the ticker (CSE: RLTY.U). Yesterday, the Company announced that it, "has secured eligibility by The Depository Trust Company (DTC) for its shares on the OTC. DTC is a subsidiary of the Depository Trust & Clearing Corp ("DTCC") that manages the electronic clearing and settlement of publicly-traded companies in the United States

DTC Eligibility - Further to the company's news release dated July 16th, 2018, Tidal Royalty's common shares are now fully DTC eligible and trade under the symbol "TDRYF" on the OTC Markets. Securities that are eligible to be electronically cleared and settled through the DTC are considered DTC eligible. This electronic method of clearing securities speeds up the receipt of stock and cash, and thus accelerates the settlement process for investors.

Tidal Royalty's CEO Paul Rosen stated: 'We are very pleased to have obtained DTC eligibility. This status will make the process of trading our stock in the United States much easier. We expect that this will make our shares available to a larger percentage of the investment market, which should improve the liquidity of our shares and therefore benefit Tidal Royalty and our shareholders.'

About Tidal Royalty - Tidal Royalty provides royalty financing to the U.S. regulated cannabis industry. Led by an executive team with extensive industry experience in Canada and the U.S., Tidal Royalty provides operators with the funding they need to grow their business. Operators benefit from non-dilutive capital and investors get top-line access to a diversified portfolio of companies that will form the future of this transformative industry."

India Globalization Capital Inc. (NYSE: IGC) has two lines of business, a legacy infrastructure business and a cannabis pharmaceutical business that has developed a lead product for treating Alzheimer's patients. The Company recently announced the launch of its branding campaign and marketing outreach for Hyalolextm, an oral cannabinoid-based supplement for the treatment of symptoms associated with Alzheimer's. "In fiscal 2018, the Company's focus was to develop and lay the foundation to commercialize cannabinoid-based alternative therapies for indications such as Alzheimer's disease, Parkinson's disease and pain. According to the Alzheimer's Association, "Alzheimer's is a brain disease that causes a slow decline in memory, thinking and reasoning skills". The name Hyalolextm is derived from the Greek prefix 'hyalo' meaning glass-like, clear, transparent. The Company's marketing and branding campaign, therefore, is entitled 'Drops of Clarity'. This initiative will commence in several states where the Company will highlight the potential benefits of Hyalolextm as a supplement to authorized cannabis physicians as well as to caregivers and patients via both a digital format and through grassroots outreach. The Company expects to utilize this methodology, in conjunction with licensing arrangements with manufacturers, to expand its reach into multiple U.S. markets and Canada. Education and product differentiation are key components for 'Drops of Clarity'," said Ram Mukunda, Chief Executive Officer of IGC.

mCig Inc. (OTC: MCIG), headquartered in Jacksonville, Florida, is a diversified company servicing the legal cannabis, hemp, and CBD markets via its lifestyle brandsmCig recently provided an update for its HEMP project and new line of CBD products, soon to be hitting the markets. "With different Company divisions getting a traction and starting to show a real growth we finally decided to jump start our CBD division with an introduction of a new line of hemp products, that will include natural skin cosmetics, full spectrum tinctures and probiotic pets edibles. Today we have all the right pieces in place together: a hemp farm run by professional farmers, experienced research and development team, led by Arkady Uryash, MD Ph.D., and strong goal-oriented sales and marketing team. The big role in our growth strategy will play online sales, where the Company will introduce its new online store but also a marketplace of CBD products from different manufacturers, long-awaited project, that only now can be a success with having on board a new team of professionals," said Paul Rosenberg, MCIG INC. Chief Executive Officer.

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) is a United States-based public company that is developing cannabinoid-based medicine and treatments focused on cancer and its side effects. The Company recently announced that it has concluded its clinical trial held at Rambam Medical Center. Launched in 2016, the study involved patients with advanced Cancer and Cancer Anorexia-Cachexia Syndrome (CACS) with Cannabics SR 5mg, daily for 3 months. The main endpoints that were examined were weight gain, appetite and Quality of Life (QOL). The official results are now being evaluated by the Hospital and the Company expects them to be published in the next few months according to Professor Gil Bar-Sela, who ran the study and is Deputy Director of the Division of Oncology at Rambam Health Care Campus, Head of the Palliative and Supportive Oncology Unit, and Head of the service for Melanoma and Sarcoma patients. Eyal Ballan, Chief Technical Officer of Cannabics Pharmaceuticals said: "We are very pleased to have completed this study. We are awaiting the results and expect them to further elucidate an important aspect of our mission in integrating cannabinoid-based therapies into the world of precision medicine; while at the same time focusing our efforts on bringing scientific data to support developments of cannabinoid-based therapies".

Future Farm Technologies Inc. (OTCQX: FFRMF) is a Canadian company with holdings throughout North America including California, Massachusetts, Florida, Maine, Puerto Rico and Newfoundland. Future Farm announced last week that it has closed on a new investment from a fund of Yorkville Advisors Global, LP. Proceeds from the private placement will be used to refinance a previous investment made by Yorkville and to support the continued development of the Company's various projects throughout North America. In addition to the financing, the Company is pleased to provide an update on operations in Puerto Rico. Three of Future Farm's senior advisers will be onsite next week in Puerto Rico to oversee the development of FFPR, LLC, which is set up to own and operate five medical dispensaries on the island. Led by Tom Barrette and George Groccia, the team will work with its partners, including Clinica Verde, to design and implement collaborative, operational management processes. Clinica Verde operates four existing Registered Marijuana Dispensaries in Puerto Rico. "Yorkville has proven to be a very supportive partner for our endeavors," comments William Gildea, Chief Executive Officer of Future Farm. "We are both committed to see our investments succeed and to expand the value of our portfolio for shareholders."

Subscribe Now! Watch us report LIVE https://www.youtube.com/FinancialBuzzMedia Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/

About FinancialBuzz.com  

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the 'Site') is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For Tidal Royalty Corp. financial news dissemination and PR services, FinancialBuzz.com has been compensated five thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com .

For further information: Media Contact: [email protected] +1-877-601-1879

Url: http://www.FinancialBuzz.com

SOURCE FinancialBuzz.com

Sponsored Post and Backlink Submission


Latest Press Release on Drug News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close